Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth

Citation:

Fried I, Beam AL, Kohane IS, Palmer NP. Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth. JAMA Intern Med. 2017;177 (11) :1689-1690. Copy at https://tinyurl.com/y7qahoxz

Date Published:

2017 Nov 01

Copyright © 2024 The President and Fellows of Harvard College | Accessibility | Digital Accessibility | Report Copyright Infringement